Technical Analysis for ACAD - ACADIA Pharmaceuticals Inc.

Grade Last Price % Change Price Change
grade C 30.43 1.13% 0.34
ACAD closed up 1.13 percent on Friday, July 21, 2017, on 79 percent of normal volume. The stock crossed above its 200 day moving average, improving its long-term outlook by crossing above that critical trendline. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Earnings due: Aug 3

Track This Stock
Watchlist Portfolio
Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Flat Up Up
See historical ACAD trend table...

Date Alert Name Type % Chg
Jul 21 Upside 200 DMA Break Bullish 0.00%
Jul 21 Upper Bollinger Band Walk Other 0.00%
Jul 20 200 DMA Resistance Bearish 1.13%
Jul 20 Stochastic Reached Overbought Other 1.13%
Jul 19 Shooting Star Candlestick Bearish 4.93%

Older signals for ACAD ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
Basic chart:

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders. The company has a pipeline of product candidates led by pimavanserin, which is in Phase III development stage for the treatment of Parkinson's disease psychosis. It is also developing pimavanserin that has completed Phase II co-therapy trials for the treatment of schizophrenia; and is in Phase II clinical trials for the treatment of Alzheimer's disease psychosis. In addition, the company, through collaboration with Allergan, Inc., is developing alpha adrenergic agonists, which are in Phase II clinical trials for the treatment of chronic pain; and muscarinic agonist that is in Phase I clinical trials for the treatment of glaucoma. Further, it is developing two advanced preclinical programs directed at Parkinson's disease and other neurological disorders. The company was formerly known as Receptor Technologies, Inc. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
Is ACAD a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 0 bearish and 4 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 40.83
52 Week Low 20.68
Average Volume 1,531,534
200-Day Moving Average 30.3769
50-Day Moving Average 27.826
20-Day Moving Average 28.6555
10-Day Moving Average 28.64
Average True Range 1.1773
ADX 15.39
+DI 25.11
-DI: 15.28
Chandelier Exit (Long, 3 ATRs) 27.0481
Chandelier Exit (Short, 3 ATRs) 29.9419
Upper Bollinger Band 30.3545
Lower Bollinger Band 26.9565
Percent B (%b) 1.02
Bandwidth 0.118581
MACD Line 0.3808
MACD Signal Line 0.1578
MACD Histogram 0.223